Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N.

J Surg Oncol. 2013 Sep;108(4):236-41. doi: 10.1002/jso.23392.

2.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM.

BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199.

3.

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.

Oncologist. 2014 Mar;19(3):266-74. doi: 10.1634/theoncologist.2013-0273. Epub 2014 Feb 25.

4.

FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S; Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD).

Pancreas. 2015 May;44(4):515-21. doi: 10.1097/MPA.0000000000000314. Review.

PMID:
25872127
5.

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.

Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T.

Ann Surg Oncol. 2015 Apr;22(4):1153-9. doi: 10.1245/s10434-014-4225-1. Epub 2014 Oct 31.

6.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

7.

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20. doi: 10.1245/s10434-015-4851-2. Epub 2015 Sep 8.

PMID:
26350368
8.

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.

Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003.

PMID:
26132367
9.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Groot Koerkamp B.

Lancet Oncol. 2016 Jun;17(6):801-10. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.

PMID:
27160474
10.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

11.

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.

Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, Burton SA.

Radiat Oncol. 2013 Oct 31;8:254. doi: 10.1186/1748-717X-8-254.

12.

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.

Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8.

13.

Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.

Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ.

Pancreatology. 2015 Nov-Dec;15(6):667-73. doi: 10.1016/j.pan.2015.08.010. Epub 2015 Sep 12.

PMID:
26412296
14.

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M.

Curr Oncol Rep. 2013 Apr;15(2):182-9. doi: 10.1007/s11912-012-0290-4. Review.

PMID:
23341367
15.

Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.

Nanda RH, El-Rayes B, Maithel SK, Landry J.

J Surg Oncol. 2015 Jun;111(8):1028-34. doi: 10.1002/jso.23921. Epub 2015 Jun 12.

PMID:
26073887
16.

Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?

Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH.

J Surg Oncol. 2016 Oct;114(5):587-596. doi: 10.1002/jso.24375. Epub 2016 Jul 21.

PMID:
27444658
17.

Localized Pancreatic Cancer: Multidisciplinary Management.

Coveler AL, Herman JM, Simeone DM, Chiorean EG.

Am Soc Clin Oncol Educ Book. 2016;35:e217-26. doi: 10.14694/EDBK_160827. Review.

18.

Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.

Addeo P, Rosso E, Fuchshuber P, Oussoultzoglou E, De Blasi V, Simone G, Belletier C, Dufour P, Bachellier P.

Oncology. 2015;89(1):37-46. doi: 10.1159/000371745. Epub 2015 Mar 7.

PMID:
25766660
19.

A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).

Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303. doi: 10.1016/j.ijrobp.2016.05.010. Epub 2016 May 24.

PMID:
27475674
20.

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.

Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, Coriat R, Regenet N, Innominato P, Taieb J, Cunha AS, Bachet JB.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1196-205. doi: 10.1245/s10434-015-4783-x. Epub 2015 Aug 14.

PMID:
26271395

Supplemental Content

Support Center